DiscoverCME in Minutes: Education in OphthalmologyNancy M. Holekamp, MD - Eyeing the Benefits and Risks of VEGF-Targeted Therapies for nAMD
Nancy M. Holekamp, MD - Eyeing the Benefits and Risks of VEGF-Targeted Therapies for nAMD

Nancy M. Holekamp, MD - Eyeing the Benefits and Risks of VEGF-Targeted Therapies for nAMD

Update: 2023-01-04
Share

Description

Please visit answersincme.com/BJH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal disease discusses strategies for treating patients with intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.
Comments 
loading
In Channel
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Nancy M. Holekamp, MD - Eyeing the Benefits and Risks of VEGF-Targeted Therapies for nAMD

Nancy M. Holekamp, MD - Eyeing the Benefits and Risks of VEGF-Targeted Therapies for nAMD

Answers in CME